Design Therapeutics EBITDA 2021-2025 | DSGN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Design Therapeutics ebitda from 2021 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Design Therapeutics ebitda from 2021 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.7B
Amgen (AMGN)	$161.5B
Gilead Sciences (GILD)	$142.5B
Vertex Pharmaceuticals (VRTX)	$123.1B
Bristol Myers Squibb (BMY)	$98.7B
GSK (GSK)	$81B
CSL (CSLLY)	$78.2B
Regeneron Pharmaceuticals (REGN)	$60.4B
Alnylam Pharmaceuticals (ALNY)	$42.1B
Argenex SE (ARGX)	$34.4B
BioNTech SE (BNTX)	$27.4B
Royalty Pharma (RPRX)	$20.3B
Biogen (BIIB)	$19.8B
Insmed (INSM)	$18.3B
Illumina (ILMN)	$15.8B
Genmab (GNMSF)	$14B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.3B
Exelixis (EXEL)	$12.3B
BioMarin Pharmaceutical (BMRN)	$11.3B
QIAGEN (QGEN)	$10.8B
Ascendis Pharma (ASND)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Regencell Bioscience Holdings (RGC)	$8.2B
Roivant Sciences (ROIV)	$7.9B